PNC27

PNC27 is presented here as a laboratory catalogue entry for research environments that need clear identification, labelled variants, and direct access to supporting records. The current listing includes 2 labelled variants: 5mg and 10mg. That structure keeps the page useful as both a procurement reference and an indexable resource covering stock visibility, pricing context, and documentation.

Within the wider Au Peptide Labs catalogue, PNC27 sits alongside Retatrutide, Tesamorelin, and Ipamorelin. Researchers often review neighbouring compounds before selecting a comparator or deciding which sequence belongs in a screening panel. Keeping those internal paths close to the product page improves traceability and helps laboratory buyers compare materials without relying on vague or consumer-style copy.

In research literature, PNC27 is generally treated as a 32-amino acid p53-MDM2 binding domain peptide fused to an HDM-2 penetratin sequence, studied for selective pore formation in cancer cell membranes in in vitro tumour cell model assays. PNC27 is constructed by fusing residues 12–26 of the p53 transactivation domain — which binds the hydrophobic cleft of MDM2 — with a penetratin-derived membrane-active sequence. The design premise is that MDM2 overexpressed on the surface of cancer cells (but not normal cells) acts as the receptor that tethers PNC27, after which the membrane-active domain inserts into the lipid bilayer and forms a pore. This leads to selective necrotic-like cell death in MDM2-overexpressing cancer cell lines in vitro, without equivalent toxicity in MDM2-low normal cell controls. This mechanism is mechanistically distinct from canonical p53 pathway restoration approaches and positions PNC27 as a tool for studying MDM2 cell-surface expression in tumour biology models.

Research panels typically pair PNC27 with MDM2-knockdown controls, MDM2-overexpressing transfectants, and p53-null cell lines to rigorously test the MDM2-surface-expression hypothesis. Its dual mechanism (MDM2 binding + membrane disruption) also makes it an informative comparator against pure MDM2 antagonists (nutlin-3a) in pathway dissection assays. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether PNC27 behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.

If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.

When teams compare PNC27 with Retatrutide, Tesamorelin, and Ipamorelin, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.